Skip to main content
. 2017 Jan 26;129(15):2111–2119. doi: 10.1182/blood-2016-11-751628

Table 3.

Univariate and multivariate analysis for OS

Model 1: ASCT patients
Univariate analysis Multivariate analysis A Multivariate analysis B
RR 95% CI P RR 95% CI P RR 95% CI P
Period
 2010-2014 Reference Reference Reference
 2005-2009 2.9 1.7-5.3 <.001 2.4 1.4-4.5 .001 2.6 1.5-5.0 <.001
 2000-2004 3.9 2.3-7.0 <.001 3.3 1.9-6.2 <.001 2.8 1.5-5.6 <.001
Age ≥ 65 1.3 0.9-1.8 .11 Not included Not included
>1 organs involved 2.2 1.7-3.0 <.001 1.7 1.2-2.4 .001 1.8 1.3-2.7 .001
dFLC ≥ 18 mg/dl 2.3 1.6-3.2 <.001 Not included 1.9 1.3-2.9 <.001
BMPCs≥10% 2.0 1.5-2.7 <.001 2.1 1.5-2.8 <.001 2.2 1.5-3.2 <.001
Full-dose melphalan conditioning 0.3 0.2-0.4 <.001 0.4 0.3-0.6 <.001 0.5 0.3-0.7 <.001
Troponin T≥0.035 ng/mL 2.7 1.9-3.8 <.001 Not included 1.6 1.01-2.4 .04
eGFR<30 mL/min/1.73 m2 1.7 0.9-2.7 .08 Not significant Not significant
Model 2: Non-ASCT patients
Univariate analysis Multivariate analysis A Multivariate analysis B
RR 95% CI P RR 95% CI P RR 95% CI P
Period
 2010-2014 Reference Not significant Not significant
 2005-2009 1.1 0.9-1.3 .3
 2000-2004 1.8 1.5-2.2 <.001
Age ≥ 65 y 1.2 1. 1-1.4 .005 1.2 1.1-1.4 .009 1.3 1.04-1.5 .01
>2 organs involved 1.4 1.1-1.6 <.001 1.4 1.2-1.7 <.001 1.3 1.04-1.5 .01
BMPCs ≥10% 1.3 1.1-1.5 .002 1.2 1.1-1.4 .008 NS
dFLC ≥18 mg/dL 1.6 1.3-1.8 <.001 NI 1.4 1.1-1.6 .001
Treatment category
 MDex Reference Reference Reference
 MP 1.9 1.6-2.4 <.001 1.6 1.2-2.1 <.001 2.0 1.4-2.8 <.001
 Bortezomib-based 1.0 0.8-1.2 .98 1.1 0.8-1.4 .58 1.0 0.8-1.4 .77
 IMiD-based 1.0 0.7-1.3 .87 1 0.7-1.4 .92 1.2 0.8-1.7 .34
 Dexamethasone alone 2.1 1.5-2.9 <.001 2.0 1.4-2.9 <.001 1.9 1.1-3.0 .02
Troponin T ≥0.035 ng/mL 2.2 1.9-2.7 <.001 NI 2.2 1.8-2.6 <.001
eGFR <30 mL/min per 1.73 m2 0.9 0.8-1.1 .53 NI NI

Boldface indicates significance at P < .05.

RR, risk ratio.